Chronic pain management using buprenorphine: Questions and considerations

Journal of Global Drug Policy and Practice

Volumn 5, Issue 1, 2011, Pages

  Pohl, Mel ^a   Smith, Logan ^a  

^a Las Vegas Recovery Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MU OPIATE RECEPTOR AGONIST; NEUROLEPTIC AGENT; OXYCODONE;

ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; COGNITIVE DEFECT; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; EUPHORIA; HUMAN; HYPERALGESIA; OPIATE ADDICTION; PAIN THRESHOLD; RESPIRATION DEPRESSION; SIDE EFFECT; TABLET FORMULATION;

EID: 79955125845     PISSN: None     EISSN: 19344708     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Khouzam, H. Chronic pain and its management in primary care. Southern Med J. 2000; 93: 946-952.
2. Koo, P. (2003). Acute pain management. J Pharm Prac. 2003; 16: 231-248.
3. Pletcher, M., Kertesz, S., Kohn, M., & Gonzales, R. Trends in opioid prescribing by race/ethnicity for patients seeking care in U.S. emergency departments. JAMA. 2008; 299: 70-78.
4. Claudill-Slosberg, M., Schwartz, L., & Woloshin, S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain, 2004; 109: 514-519.
5. Ballantyne, J. Opioid controls: Regulate to educate. Pain Med. 2010; 11: 480-481.
6. Zee, A. The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. Am J Pub Health. 2009; 99: 221-227.
7. Kuehn, B. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA, 2007; 297: 249-251.
8. Paulozzi, L., Budnitz, D., & Xi, Y. (2006). Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiology and Drug Safety. 2006; 15: 618-627.
9. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The TEDS Report: Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008. 2010, Rockville, MD. http://www.oas.samhsa.gov/2k10/230/230PainRelvr2k10.htm (Retrieved 7/16/10).
10. Portenoy, R., & Foley, K. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain. 1986; 25: 171-186.
11. Chou, R., Fanciullo, G., Fine, P., Adler, J., Ballantyne, J., Davies, P., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10: 113-130.
12. Kuehn, B. (2009). Efforts aim to curb opioid deaths, injuries. JAMA, 301, 1213-1215.
13. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: Trends in Nonmedical Use of Prescription Pain Relievers: 2002 to 2007. 2009, Rockville, MD. http://oas.samhsa.gov/2k9/painRelievers/nonmedicalTrends.pdf (Retrieved 7/13/10).
14. Montgomery, H., Miller, W., & Tonigan, S. Does Alcoholics Anonymous involvement predict treatment outcome? J Substance Abuse Treatment. 1995; 12: 241-246.
15. Substance Abuse and Mental Health Services Administration (a). Buprenorphine physician and treatment locator. 2010, SAMHSA, http://buprenorphine.samhsa.gov/bwns_locator/aboutphysician.htm (Retrieved 8/30/10).
16. Substance Abuse and Mental Health Services Administration (b). Substance Abuse Treatment Facility Locator. 2010, SAMHSA, http://www.findtreatment.samhsa.gov/ (Retrieved 8/30/10).
17. Jaffe, J., & O'checkentityKeefe, C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Dep. 2003; 70: S3-S11.
18. Sullivan, L., Chawarski, M., O'checkentityConnor, P., Schottenfeld, R., & Fiellin, D. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Dep. 2005; 79: 113-116.
19. Walsh, S., Preston, K., Bigelow, G., & Stitzer, M. Acute administration of Buprenorphine in humans: partial agonist and blockade effects. J Pharm and Exp Ther. 1995; 274: 361-372.
20. Jones, H. Practical considerations for the clinical use of buprenorphine. Science and Practice Perspectives. 2004; 2: 4-23.
21. Induru, R., & Mellar, D. Buprenorphine for neuropathic pain - targeting hyperalgesia. Am J Hosp and Palliative Med. 2009; 26: 470-473.
22. Spanagel, R., & Shippenberg, T. Modulation of morphine-induced sensitization by endogenous K opioid systems in the rat. Neuroscience Letters. 1993; 153: 232-236.
23. Emrich, H., Vogt, P., & Herz, A. Possible antidepressive effects of opioids: action of buprenorphine. Annals of the New York Academy of Science. 1982; 398: 108-112.
24. Nutt, D., & Groves, S. Buprenorphine and schizophrenia. Human Psychopharm. 1991; 6: 71-73.
25. Walsh, S., Preston, K., Stitzer, M., Cone, E., & Bigelow, G. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics. 1994; 55: 569-580.
26. Stoller, K., Bigelow, G., Walsh, S., & Strain, E. Effects of buprenorphine/naloxone in opioid dependent humans. Psychopharm. 2001; 154: 230-242.
27. Monte, A., Mandell, T., Wilford, B., Tennyson, J., & Boyer, E. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addictive Diseases. 2009; 28: 226-231.
28. McCance-Katz, E., & Mandell, T. Drug interactions of clinical importance with methadone and buprenorphine. Am J on Addictions. 2009; 19: 2-3.
29. Springer, S., Chen, S., & Altice, F. Improved HIV and substance abuse treatment outcomes for released HIV prisoners: the impact of Buprenorphine treatment. J of Urban Health: Bulletin of the New York Academy of Medicine. 2010; 87: 592-602.
30. Lobmaier, P., Gossop, M., Waal, H., & Bramness, J. The pharmacological treatment of opioid addiction - a clinical perspective. Eur J Clin Pharm. 2010; 66: 537-545.
31. Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (Review). Cochrane Database of Systematic Reviews. 2009; 4: CD005031.
32. Compton, M. (1994). Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. Journal of Pain and Symptom Management, 9, 462-473.
33. Compton, P., Charuvastra, V., & Ling, W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Dep. 2001; 63: 139-146.
34. Alford, D., Compton, P., & Samet, J. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of Internal Med. 2006; 144: 127-134.
35. Cowen, A., Lewis, J., & Macfarlane, I. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. British J Pharm. 1977; 60: 537-545.
36. Harrington, C., & Zaydfudim, V. Buprenorphine maintenance therapy hinders acute pain management in trauma. Am Surgeon. 2010; 76: 397-399.
37. Shi, J., Zhao, L.-Y., Copersino, M., Fang, Y.-X., Chen, Y., Tian, J., et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharm. 2008; 579: 160-166.